

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at the University of Oxford (SGC). Since 2008 he is a Professor at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and since 2012 Director for Chemical Biology at the Target Discovery Institute (TDI). His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules acting as reader domains of the epigenetic code.